Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0066-782x2010001400001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unpacking Performance Factors of Innovation Systems and Studying Germany's Attempt to Foster the Role of the Patient Through a Market Access Pathway for Digital Health Applications (DiGAs): Exploratory Mixed Methods Study.
J Med Internet Res
January 2025
Working Group for Data-Driven Innovation, Hamburg University of Technology, Hamburg, Germany.
Background: Health care innovation faces significant challenges, including system inertia and diverse stakeholders, making regulated market access pathways essential for facilitating the adoption of new technologies. The German Digital Healthcare Act, introduced in 2019, offers a model by enabling digital health applications (DiGAs) to be reimbursed by statutory health insurance, improving market access and patient empowerment. However, the factors influencing the success of these pathways in driving innovation remain unclear.
View Article and Find Full Text PDFPoint prevalence survey of antibiotic use in Mexican secondary care hospitals.
PLoS One
January 2025
National Institute of Public Health of Mexico, Center for Evaluation and Surveys Research, Cuernavaca, Morelos, Mexico.
Article Synopsis
- Addressing the increasing concern of antimicrobial resistance (AMR) requires better management of antibiotic prescriptions, and monitoring practices in hospitals can help optimize their use, especially in smaller facilities with limited resources.
- This study performed point prevalence surveys (PPSs) in two hospitals in Mexico to assess antibiotic prescribing patterns and collected data from 127 patients across various ward types.
- Results showed high rates of antibiotic use (60.4% and 70.5% at hospitals H1 and H2, respectively), with common indications being medical and preoperative prophylaxis, primarily based on empirical prescribing without sufficient post-prescription reviews.
Factors in Initial Anticoagulation Choice in Hospitalized Patients With Pulmonary Embolism.
JAMA Netw Open
January 2025
Department of Emergency Medicine, University of Massachusetts Chan Medical School-Baystate, Springfield.
Importance: Despite guideline recommendations to use low-molecular-weight heparins (LMWHs) or direct oral anticoagulants in the treatment of most patients with acute pulmonary embolism (PE), US-based studies have found increasing use of unfractionated heparin (UFH) in hospitalized patients.
Objective: To identify barriers and facilitators of guideline-concordant anticoagulation in patients hospitalized with acute PE.
Design, Setting, And Participants: This qualitative study conducted semistructured interviews from February 1 to June 3, 2024, that were recorded, transcribed, and analyzed in an iterative process using reflexive thematic analysis.
Clinical Inertia in the Diagnosis and Management of Hypertension Following Ambulatory Blood Pressure Monitoring.
Am J Hypertens
December 2024
Center for Behavioral Cardiovascular Health, Department of Medicine, Columbia University Irving Medical Center.
Background: Clinical inertia is common when blood pressure (BP) is high in the office. Little is known about the extent of clinical inertia after ambulatory BP monitoring (ABPM).
Methods: This was an electronic health record-based retrospective cohort study of patients with high office BP (≥140/90 mmHg) referred for ABPM at a medical center in New York City between 2016 and 2020.
Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.
Diabetes Obes Metab
December 2024
Novo Nordisk India Private Limited, Bangalore, India.
Aims: To investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co-formulation of basal, and bolus insulin, in a real-world setting.
Materials And Methods: A 20-week, prospective, single-arm, open-label, non-interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti-hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon-like peptide-1 receptor agonists. The primary endpoint was a change in HbA from baseline to end of the study; the secondary endpoints included a change in fasting plasma glucose and Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!